Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back
Leading European HTAs Call For Further Data Collection, Responsible Pricing
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
